EXPIRED
Notice Number: NOT-DK-19-019
Key Dates
Release Date: September 25, 2019
First Available Due Date: February 5, 2020
Expiration Date: January 8, 2022
PA-19-055, Research Project Grant (Parent R01 Clinical Trial Required)
PA-19-056, NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-18-330, Investigator-Initiated Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)
Issued by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Center for Complementary and Integrative Health (NCCIH)
Purpose
The purpose of this Notice of Special Interest is to foster collaborative research between nutrition researchers and experts in omics technologies and encourages applications that employ nutrigenetics and/or nutrigenomics approaches to basic, translational and clinical nutrition research. Collaboration between investigators with demonstrated expertise in nutrition research and omics techniques is highly encouraged.
Examples of the application of nutrigenetics and nutrigenomics approaches to nutrition research include but are not limited to:
Potential applicants to National Center for Comprehensive and Integrative Health (NCCIH) are encouraged to read the following information on IC-specific research interests.
The National Center for Complementary and Integrative Health (NCCIH) is particularly interested in nutrigenetic and nutigenomic-based mechanistic studies of interaction and competition between nutrient-nutrient, nutrient-drug, dietary supplements, and probiotics/prebiotics on host-microbial metabolism, immunologic/inflammatory signaling, neuro-hormonal pathways and target tissues [including bio-availability, absorption, transport, metabolism and excretion studies] that impact the basic fundamentals that will eventually lead to a better understanding of the gut brain function in health promotion and disease prevention. NCCIH is also interested in the impact of [selected] nutrient, dietary supplements, the ketogenic diet, and probiotic/prebiotic modulation of specific conditions including pain. In addition, NCCIH is interested in supporting applications studying mechanisms of how botanical products, prebiotics, Omega-3 fatty acids and other dietary supplements, in delineating their relationship to pain and inflammation. NCCIH will not support trials for the prevention and treatment of cancer.
Application and Submission Information
This Notice applies to due dates on or after February 5, 2020 and expires on January 8, 2022.
The following funding opportunity announcements (FOAs) or their reissued equivalents must be used for submissions for this initiative. Although NIDDK and NCCIH are not listed as Participating Organizations in all the FOAs listed below, applications for this initiative will be accepted.
Applications in response to this Notice that do not involve clinical trials must be submitted through PA-19-056, NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed). All instructions for PA-19-056 must be followed. Applications proposing clinical trials must be submitted through PA-18-330, Investigator-Initiated Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required) or PA-19-055 (Research Project Grant, Clinical Trial Parent R01) and follow NOT-AT-19-011, NCCIH Only Accepts Clinical Trial Applications Proposing Mechanistic Studies for Clinical Trial Parent R01 Announcements.
Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with the IC program officers listed on this NOSI, well in advance of the application due date.
Activity Code | FOA Number and Title | First Available Due Date |
R01 | PA-19-055: Research Project Grant (Parent R01 Clinical Trial Required) | February 5, 2020 |
R01 | PA-19-056: NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) | February 5, 2020 |
R01 | PA-18-330: Investigator-Initiated Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required) | February 5, 2020 |
For funding consideration, applicants must include NOT-DK-19-019 in the Agency Routing Identifier field (Box 4.b) of the SF 424 (R&R) Form. Applications without this information in Box 4.b will not be considered for this initiative.
Applications nonresponsive to the terms of this Notice will not be considered for this initiative.
Inquiries
Please direct all inquiries to:
Padma Maruvada
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: ( 301) 594-8884
Email: padma.maruvada@nih.gov
Yisong Wang
National Center for Complementary and Integrative Health (NCCIH)
Telephone: (301) 480-9483
Email: yisong.wang@nih.gov